Amyotrophic Lateral Sclerosis

Evaluating SAR443820, a RIPK1 Inhibitor, in Amyotrophic Lateral Sclerosis: Insights from the Phase 2 HIMALAYA Trial

By MedXY 10/05/2026

This phase 2 trial assessed SAR443820, a RIPK1 inhibitor, in ALS patients; it showed no clinical efficacy and increased hepatic side effects, indicating limited therapeutic potential in ALS.

Neurology news

Long-Term Tofersen Therapy in SOD1-ALS: Early Initiation Preserves Function and Extends Survival

By MedXY 02/11/2026

The integrated analysis of the VALOR trial and its open-label extension reveals that early initiation of tofersen significantly slows functional decline, preserves respiratory capacity, and improves survival in patients with SOD1-ALS over a follow-up period of up to 3.5 years.

Neurology news Public Health

Unraveling the Link Between Traumatic Brain Injury and ALS Risk: Insights From a Large UK Cohort Study

By MedXY 10/05/2025

A large retrospective cohort study reveals a transient association between traumatic brain injury (TBI) and elevated amyotrophic lateral sclerosis (ALS) risk, suggesting early ALS symptoms may predispose to injury rather than TBI causing ALS.